RESEARCH AUSTRALIA AND VAXXAS PUT AUSTRALIAN HEALTH INNOVATION ON THE NATIONAL AGENDA
The national peak body for health and medical research and innovation, Research Australia has partnered with Australian biotech company, Vaxxas, to bring around 70 health innovators together with Government to identify policy solutions to support the uptake of Australian health innovations here at home.
The Policy Roundtable, kindly hosted by the Australian National University, will be used to explore what’s required by Australian enterprise to enable it to more consistently articulate the vital next steps from R&D to procurement, and subsequent marketing and sales.
Following the Roundtable, a Parliamentary Friends of Health and Medical Research event will take place at Parliament House, hosted at the Speaker’s Courtyard by Speaker of the House of Representatives, Hon Milton Dick MP to celebrate the success stories of Australian health innovation and the opportunities the sector presents to further Australian health and wealth.
“Australian health innovation represents 28% of all Australian R&D activity.1 Australia is leading the world in many health technologies, bringing them to market is key to facilitating better commercial, economic and social outcomes for Australia and Australians,” said Nadia Levin, CEO & Managing Director of Research Australia.
“The Australian Government’s recently announced ‘A Future Made in Australia’ initiative and the National Reconstruction Fund are welcome, innovative new public policies, but more can be done to drive Australian medical, biotech and health innovation for the benefit of Australians’ health and wealth.
“Today we put Australian health innovation on the national agenda," Ms Levin said.
One of a number of Australian healthcare innovators represented at today’s events, Vaxxas is developing an innovative needle-free technology that will be fundamental to transforming the way vaccines are delivered in the future with its high-density microarray patch (HD-MAP) technology.
Vaxxas President and CEO, David Hoey said, “Vaxxas takes its role as a leader in Australian health innovation seriously. We want to do everything we can to support a flourishing national health innovation sector.
“We know firsthand the challenges Australian health innovators can face in accessing procurement and traversing complex regulatory pathways, among others. It’s great to be working with Research Australia to bring everyone together to identify policy solutions that can advance the whole sector.”
The key insights gathered from the Roundtable will be developed into policy proposals for future consideration by Government and all political parties at the Commonwealth level.
1https://researchaustralia.org/category/hmr-facts/
Media Contact: Hayden Nichols – 0478 100 424